First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.